Tin tức & Cập nhật

Investigational agent works well for migraine in pooled analysis

Treatment with the investigational agent AXS-07 significantly alleviates pain and most bothersome symptoms (MBS) in patients with migraine, according to results of a pooled analysis of the phase III MOMENTUM and INTERCEPT trials presented at AAN 2024.

SGLT2 inhibitors a promising gout medication in T2D

The use of sodium-glucose cotransporter type 2 (SGLT2) inhibitors lowers the risk of incident gout or recurrent gout flares among patients with type 2 diabetes who are taking metformin, as shown in a study.

Erenumab helps with rosacea-associated flushing, erythema

Monthly subcutaneous injections of the anti–CGRP-receptor monoclonal antibody erenumab appear to be beneficial in the management of flushing and chronic redness among individuals with rosacea, according to a study.

[Infographic] Hướng dẫn sử dụng thuốc nhỏ mũi đúng cách

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

Tirbanibulin 1% ointment proves safe and effective in patients with multiple actinic keratoses (AKs) treated in real-world settings, as shown in a study.

Do GLP1 receptor agonists increase thyroid cancer risk?

Use of glucagon-like peptide 1 (GLP1) receptor agonists does not contribute to an elevated risk of thyroid cancer, as shown in a Scandinavian cohort study with a mean follow-up of nearly 4 years.

LDL-C lowering with bempedoic acid reduces cardiovascular events in high-risk population

The use of bempedoic acid helps lower low-density lipoprotein cholesterol (LDL-C) levels and subsequently reduce cardiovascular events in individuals at high cardiovascular risk, according to the CLEAR* Outcomes trial.

Olezarsen reduces triglyceride levels in adults with hypertriglyceridemia

Monthly administration of olezarsen 50 or 80 mg significantly reduced triglyceride levels in patients with predominantly moderate hypertriglyceridemia (HTG) and elevated cardiovascular (CV) risk, according to the Bridge-TIMI 73a trial presented at ACC.24.